Brief: Valneva Reports 95% Seroresponse Four Years After IXCHIQ Vaccination
30/09/2025 06:12
Sept 30 (Reuters) - Valneva SE VLS.PA: REPORTS 95% SERORESPONSE FOUR YEARS AFTER SINGLE SHOT OF CHIKUNGUNYA VACCINE IXCHIQ Source text: ID:nGNX5K3mwk Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency